X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Orchid Chemicals with MYLAN INC. - US - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ORCHID PHARMA LTD vs MYLAN (US) - Comparison Results

ORCHID PHARMA LTD    Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 ORCHID PHARMA LTD   MYLAN
EQUITY SHARE DATA
    ORCHID PHARMA LTD
Sep-13
MYLAN
Dec-14
ORCHID PHARMA LTD/
MYLAN
5-Yr Chart
Click to enlarge
High Rs1943,867-   
Low Rs352,725-   
Sales per share (Unadj.) Rs276.51,324.0-  
Earnings per share (Unadj.) Rs-79.2159.5-  
Cash flow per share (Unadj.) Rs-43.5256.7-  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs53.9658.1-  
Shares outstanding (eoy) m70.45378.37-   
Bonus/Rights/Conversions ESOPOI-  
Price / Sales ratio x0.42.5 16.6%   
Avg P/E ratio x-1.420.7 -7.0%  
P/CF ratio (eoy) x-2.612.8 -20.5%  
Price / Book Value ratio x2.15.0 42.4%  
Dividend payout %00-   
Avg Mkt Cap Rs m8,0671,247,263 0.6%   
No. of employees `0002.825.0 11.2%   
Total wages/salary Rs m2,5270-   
Avg. sales/employee Rs Th6,956.120,038.0 34.7%   
Avg. wages/employee Rs Th902.50-   
Avg. net profit/employee Rs Th-1,993.02,413.9 -82.6%   
INCOME DATA
Net Sales Rs m19,477500,951 3.9%  
Other income Rs m407-2,920 -13.9%   
Total revenues Rs m19,884498,031 4.0%   
Gross profit Rs m1,103124,589 0.9%  
Depreciation Rs m2,51936,793 6.8%   
Interest Rs m5,22721,608 24.2%   
Profit before tax Rs m-6,23663,268 -9.9%   
Minority Interest Rs m20-260 -7.6%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m5110-   
Tax Rs m-1252,660 -4.7%   
Profit after tax Rs m-5,58060,348 -9.2%  
Gross profit margin %5.724.9 22.8%  
Effective tax rate %2.04.2 47.7%   
Net profit margin %-28.712.0 -237.8%  
BALANCE SHEET DATA
Current assets Rs m11,014440,402 2.5%   
Current liabilities Rs m32,060344,306 9.3%   
Net working cap to sales %-108.119.2 -563.3%  
Current ratio x0.31.3 26.9%  
Inventory Days Days9578 121.5%  
Debtors Days Days34107 31.3%  
Net fixed assets Rs m29,440115,894 25.4%   
Share capital Rs m70517,715 4.0%   
"Free" reserves Rs m2,0430-   
Net worth Rs m3,800249,022 1.5%   
Long term debt Rs m9,018372,014 2.4%   
Total assets Rs m46,5101,003,037 4.6%  
Interest coverage x-0.23.9 -4.9%   
Debt to equity ratio x2.41.5 158.9%  
Sales to assets ratio x0.40.5 83.8%   
Return on assets %-0.88.2 -9.3%  
Return on equity %-146.924.2 -606.0%  
Return on capital %-3.713.6 -27.4%  
Exports to sales %37.90-   
Imports to sales %22.60-   
Net fx Rs m1,8650-   
CASH FLOW
From Operations Rs m1,68265,850 2.6%  
From Investments Rs m-9,860-51,931 19.0%  
From Financial Activity Rs m6,644-17,352 -38.3%  
Net Cashflow Rs m-1,535-3,433 44.7%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 64.89 Rs / USD

Compare ORCHID PHARMA LTD With: ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare ORCHID PHARMA LTD With: SUVEN LIFE  NOVARTIS  SANOFI INDIA  PLETHICO PHARMA  VENUS REMEDIES  



Today's Market

Sensex Opens Firm; Healthcare & Metal Stocks Gain(09:30 am)

Asian stocks are higher today as Chinese and Hong Kong shares show gains. The Shanghai Composite is up 0.17% while the Hang Seng is up 0.95%. The Nikkei 225 is trading up by 0.4%.

Related Views On News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ORCHID PHARMA LTD SHARE PRICE


Feb 23, 2018 10:37 AM

TRACK ORCHID PHARMA LTD

  • Track your investment in ORCHID PHARMA LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ORCHID PHARMA LTD

ORCHID PHARMA LTD 5-YR ANALYSIS

COMPARE ORCHID PHARMA LTD WITH

MARKET STATS